MA31072B1 - Composes tetrahydrocyclopenta [b] indole comme modulateurs du recepteur des androgenes - Google Patents

Composes tetrahydrocyclopenta [b] indole comme modulateurs du recepteur des androgenes

Info

Publication number
MA31072B1
MA31072B1 MA32013A MA32013A MA31072B1 MA 31072 B1 MA31072 B1 MA 31072B1 MA 32013 A MA32013 A MA 32013A MA 32013 A MA32013 A MA 32013A MA 31072 B1 MA31072 B1 MA 31072B1
Authority
MA
Morocco
Prior art keywords
formula
tetrahydrocyclopenta
modulators
compound
androgen receptor
Prior art date
Application number
MA32013A
Other languages
English (en)
Inventor
Konstantinos Gavardinas
Jonathan Edward Green
Prabhakar Kondaji Jadhav
Donald Paul Matthews
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA31072B1 publication Critical patent/MA31072B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN COMPOSÉ DE FORMULE : FORMULE (I) OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT LE COMPOSÉ AA DE FORMULE (I) EN ASSOCIATION AVEC UN TRANSPORTEUR APPROPRIÉ, UN DILUANT, OU UN EXCIPIENT; ET DES PROCÉDÉS POUR TRAITER DES TROUBLES PHYSIOLOGIQUES, EN PARTICULIER UNE MASSE OSSEUSE RÉDUITE, UNE OSTÉOPOROSE, UNE OSTÉOPÉNIE, OU UNE MASSE OU FORCE MUSCULAIRE RÉDUITE, COMPRENANT L'ADMINISTRATION D'UN COMPOSÉ DE FORMULE (I), OU D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI.
MA32013A 2006-11-20 2009-06-17 Composes tetrahydrocyclopenta [b] indole comme modulateurs du recepteur des androgenes MA31072B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86648406P 2006-11-20 2006-11-20

Publications (1)

Publication Number Publication Date
MA31072B1 true MA31072B1 (fr) 2010-01-04

Family

ID=39415431

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32013A MA31072B1 (fr) 2006-11-20 2009-06-17 Composes tetrahydrocyclopenta [b] indole comme modulateurs du recepteur des androgenes

Country Status (36)

Country Link
US (1) US7968587B2 (fr)
EP (1) EP2094658B1 (fr)
JP (1) JP5399259B2 (fr)
KR (1) KR101121471B1 (fr)
CN (1) CN101541749B (fr)
AR (1) AR063559A1 (fr)
AT (1) ATE538091T1 (fr)
AU (1) AU2007324046B2 (fr)
BR (1) BRPI0719092B8 (fr)
CA (1) CA2670340C (fr)
CL (1) CL2007003182A1 (fr)
CO (1) CO6190513A2 (fr)
CR (1) CR10802A (fr)
CY (1) CY1112284T1 (fr)
DK (1) DK2094658T3 (fr)
EA (1) EA015627B1 (fr)
EC (1) ECSP099350A (fr)
ES (1) ES2376048T3 (fr)
HR (1) HRP20120032T1 (fr)
IL (1) IL198410A (fr)
JO (1) JO2800B1 (fr)
MA (1) MA31072B1 (fr)
MX (1) MX2009005251A (fr)
MY (1) MY154547A (fr)
NO (1) NO342531B1 (fr)
NZ (1) NZ576296A (fr)
PE (1) PE20081161A1 (fr)
PL (1) PL2094658T3 (fr)
PT (1) PT2094658E (fr)
RS (1) RS52191B (fr)
SI (1) SI2094658T1 (fr)
TN (1) TN2009000189A1 (fr)
TW (1) TWI398438B (fr)
UA (1) UA98777C2 (fr)
WO (1) WO2008063867A2 (fr)
ZA (1) ZA200903096B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0907844B8 (pt) 2008-02-22 2021-05-25 Radius Health Inc compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
EA019713B1 (ru) * 2008-05-16 2014-05-30 Эли Лилли Энд Компани ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ
AR078862A1 (es) 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
JP5964756B2 (ja) 2010-02-04 2016-08-03 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
PL2568806T3 (pl) 2010-05-12 2017-03-31 Radius Health, Inc. Schematy lecznicze
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
BR112013028895A2 (pt) 2011-05-10 2016-08-09 Bayer Ip Gmbh (tio)carbonilamidinas bicíclicas
CN103265479B (zh) * 2013-06-14 2017-12-08 南开大学 一种6‑氯甲基烟酸叔丁酯的合成方法
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
WO2017223115A1 (fr) 2016-06-22 2017-12-28 Radius Health, Inc. Méthodes ar+ de traitement du cancer du sein
US20180185347A1 (en) 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
EP3565542B1 (fr) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Formes polymorphes de rad1901-2hcl
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
US12441745B2 (en) 2019-02-12 2025-10-14 Radius Pharmaceuticals, Inc. Processes and compounds
AU2021213297A1 (en) * 2020-01-27 2022-08-18 Eirgen Pharma Ltd. Tetrahydrocyclopenta[b]indole compounds for the treatment of renal disease
US11986461B1 (en) * 2023-08-24 2024-05-21 King Faisal University 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-2-ol as an antitumor and antimicrobial compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988820A (en) 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
GB8924392D0 (en) 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
GB9008108D0 (en) 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
DE4027278A1 (de) 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
DE4131346A1 (de) 1991-09-20 1993-03-25 Bayer Ag Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
AU7558900A (en) * 1999-10-14 2001-04-23 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline derivatives
JP2005527464A (ja) 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターとしてのシクロヘプタＢインドール誘導体
DE10164564B4 (de) 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
EP2423190A1 (fr) 2002-05-16 2012-02-29 Shionogi&Co., Ltd. Composés présentant un antagonisme du récepteur PGD 2
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
WO2005092854A1 (fr) * 2004-03-03 2005-10-06 Eli Lilly And Company Modulateurs de recepteur nucleaire d'hormones steroides a base de derives indole substitues bicycliques
JP2008520674A (ja) * 2004-11-22 2008-06-19 スミスクライン ビーチャム コーポレーション Ｈｃｖインヒビター
EP1817025A2 (fr) 2004-11-23 2007-08-15 PTC Therapeutics, Inc. Tetrahydrocarbazoles en tant qu'agents actifs permettant d'inhiber la production de vegf par regulation de la traduction
JP2008530229A (ja) 2005-02-17 2008-08-07 ワイス シクロアルキル縮合インドール、ベンゾチオフェン、ベンゾフランおよびインデン誘導体
AU2006262283B2 (en) 2005-06-24 2011-10-13 Eli Lilly And Company Tetrahydrocarbazole derivatives useful as androgen receptor modulators (SARM)
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
WO2008019825A1 (fr) 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Utilisation de dérivés d'indole tricycliques pour le traitement de maladies musculaires
EA019713B1 (ru) 2008-05-16 2014-05-30 Эли Лилли Энд Компани ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ

Also Published As

Publication number Publication date
HRP20120032T1 (hr) 2012-02-29
JO2800B1 (en) 2014-03-15
BRPI0719092A2 (pt) 2013-12-03
US7968587B2 (en) 2011-06-28
MY154547A (en) 2015-06-30
PL2094658T3 (pl) 2012-05-31
US20100069404A1 (en) 2010-03-18
WO2008063867A2 (fr) 2008-05-29
CL2007003182A1 (es) 2008-06-27
ZA200903096B (en) 2010-07-28
CN101541749B (zh) 2013-03-27
DK2094658T3 (da) 2012-02-13
EA015627B1 (ru) 2011-10-31
CY1112284T1 (el) 2015-12-09
UA98777C2 (en) 2012-06-25
ES2376048T3 (es) 2012-03-08
WO2008063867A3 (fr) 2008-07-31
CA2670340C (fr) 2014-05-20
PE20081161A1 (es) 2008-08-15
ECSP099350A (es) 2009-06-30
KR20090082229A (ko) 2009-07-29
TW200827347A (en) 2008-07-01
BRPI0719092B8 (pt) 2021-05-25
EA200970500A1 (ru) 2009-10-30
NO342531B1 (no) 2018-06-11
JP5399259B2 (ja) 2014-01-29
JP2010510231A (ja) 2010-04-02
IL198410A0 (en) 2010-02-17
KR101121471B1 (ko) 2012-02-28
TN2009000189A1 (en) 2010-10-18
AU2007324046A1 (en) 2008-05-29
AR063559A1 (es) 2009-02-04
BRPI0719092B1 (pt) 2020-08-18
NO20092103L (no) 2009-05-28
ATE538091T1 (de) 2012-01-15
TWI398438B (zh) 2013-06-11
CN101541749A (zh) 2009-09-23
HK1134089A1 (en) 2010-04-16
CA2670340A1 (fr) 2008-05-29
RS52191B (sr) 2012-10-31
CR10802A (es) 2009-07-13
SI2094658T1 (sl) 2012-04-30
EP2094658B1 (fr) 2011-12-21
IL198410A (en) 2013-09-30
NZ576296A (en) 2011-11-25
CO6190513A2 (es) 2010-08-19
EP2094658A2 (fr) 2009-09-02
AU2007324046B2 (en) 2012-04-05
PT2094658E (pt) 2012-02-22
MX2009005251A (es) 2009-08-19

Similar Documents

Publication Publication Date Title
WO2008063867A3 (fr) Composés tétrahydrocyclopenta[b] indole comme modulateurs du récepteur des androgènes
WO2009140448A8 (fr) Modulateurs des récepteurs aux androgènes tétrahydrocyclopenta[b]indoles
WO2006124447A3 (fr) N-arylpyrrolidines substituees utilisees comme modulateurs selectifs du recepteur des androgenes
WO2007002181A3 (fr) Derives tetrahydrocarbazole convenant comme modulateurs du recepteur d'angrogene
MA29791B1 (fr) Composes therapeutiques.
MA31087B1 (fr) Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde.
MA29685B1 (fr) Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques
MA30672B1 (fr) Utilisation de derives de l'azabicyclo hexane
UA99132C2 (ru) Производные дикарбоновых кислот как агонисты рецепторов s1p1
EP2966065A3 (fr) Pyrimidines cyclopenta [d] hydroxylées et méthoxylées utilisées en tant qu'inhibiteurs de la protéine kinase akt
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
CA2360313A1 (fr) Modulateurs selectifs de recepteur de glucocorticoide
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
CA2360308A1 (fr) Modulateurs selectifs de recepteur de glucocorticoide
UA86621C2 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
SI1957484T1 (sl) Antagonisti glukagonskega receptorja, priprava in terapevtske uporabe
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
WO2006070325A3 (fr) Derives de 2,3,4,9-tetrahydro-1h-carbazole utilises en tant qu'antagonistes des recepteurs de crth2
RU2008119410A (ru) Диспергируемые таблетки, включающие деферасирокс
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
AU2003214535A8 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2006018708A3 (fr) Derives de pyrrolidine utilises en tant qu'antagonistes des recepteurs muscariniques
MX2007011280A (es) Dipirazoles como farmacos del sistema nervioso central.
MX2007005824A (es) Agonistas y antagonistas del receptor de somatostatina.
TW201240659A (en) (5s,8s)-3-(4'-chloro-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one(compound a) for therapy